Pages that link to "Q44370378"
Jump to navigation
Jump to search
The following pages link to Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment (Q44370378):
Displaying 50 items.
- Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approach (Q22305854) (← links)
- A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis (Q24644684) (← links)
- The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors (Q24681206) (← links)
- Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations (Q26765300) (← links)
- Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action (Q26822611) (← links)
- Sphingosine-1-phosphate receptor 1 signalling in T cells: trafficking and beyond (Q27011857) (← links)
- Sphingolipids in spinal cord injury (Q27026103) (← links)
- FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis (Q28288357) (← links)
- Development of oral immunomodulatory agents in the management of multiple sclerosis (Q28388704) (← links)
- Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli? (Q28546716) (← links)
- FTY720 reduces post-ischemic brain lymphocyte influx but does not improve outcome in permanent murine cerebral ischemia (Q28743446) (← links)
- FcRγ-dependent immune activation initiates astrogliosis during the asymptomatic phase of Sandhoff disease model mice (Q29248442) (← links)
- Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes (Q30427148) (← links)
- Stereochemistry-activity relationship of orally active tetralin S1P agonist prodrugs. (Q30432808) (← links)
- Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future? (Q33209050) (← links)
- Tissue-resident exhausted effector memory CD8+ T cells accumulate in the retina during chronic experimental autoimmune uveoretinitis (Q33563989) (← links)
- Discovery of a Potent, S1P3-Sparing Benzothiazole Agonist of Sphingosine-1-Phosphate Receptor 1 (S1P1) (Q33598742) (← links)
- Optimization of a Potent, Orally Active S1P1 Agonist Containing a Quinolinone Core. (Q33630400) (← links)
- Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations. (Q33651898) (← links)
- Altered Expression of Signaling Genes in Jurkat Cells upon FTY720 Induced Apoptosis (Q33721924) (← links)
- T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis (Q33723154) (← links)
- Myelin recovery in multiple sclerosis: the challenge of remyelination (Q33772195) (← links)
- Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis (Q33810559) (← links)
- Developing therapeutics for the treatment of multiple sclerosis (Q33946995) (← links)
- FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination (Q34105944) (← links)
- Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved (Q34153221) (← links)
- The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2 (Q34274256) (← links)
- New approaches in the management of multiple sclerosis (Q34389528) (← links)
- FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation (Q34490581) (← links)
- "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets (Q34593159) (← links)
- Fingolimod for relapsing multiple sclerosis: an update. (Q34618474) (← links)
- Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis (Q34624835) (← links)
- Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis (Q34630494) (← links)
- FTY720/fingolimod, a sphingosine analogue, reduces amyloid-β production in neurons. (Q34718530) (← links)
- Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis (Q34729032) (← links)
- Anti-inflammatory effects of FTY720 do not prevent neuronal cell loss in a rat model of optic neuritis (Q34805735) (← links)
- Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model (Q34813347) (← links)
- Sphingosine 1-phosphate and its G protein-coupled receptors constitute a multifunctional immunoregulatory system (Q35012573) (← links)
- Fingolimod modulates microglial activation to augment markers of remyelination (Q35154946) (← links)
- Egress: a receptor-regulated step in lymphocyte trafficking (Q35216962) (← links)
- High-affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis. (Q35223938) (← links)
- Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). (Q35589934) (← links)
- Sphingosine 1-phosphate and its type 1 G protein-coupled receptor: trophic support and functional regulation of T lymphocytes (Q35675105) (← links)
- Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules (Q35684358) (← links)
- Insights into the pharmacological relevance of lysophospholipid receptors (Q35853199) (← links)
- FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value (Q35876398) (← links)
- Regulation of immunity by lysosphingolipids and their G protein-coupled receptors (Q35971421) (← links)
- FTY720 suppresses interleukin-1beta-induced secretory phospholipase A2 expression in renal mesangial cells by a transcriptional mechanism (Q36052555) (← links)
- Immune modulating peptides for the treatment and suppression of multiple sclerosis (Q36151968) (← links)
- Development and Effects of FTY720 Ophthalmic Solution on Corneal Allograft Survival (Q36272747) (← links)